Lighting up Antigen Design with AI

We built the first AI platform to move beyond binding affinity and predict true T-cell immunogenicity. De-risk your pipeline, accelerate discovery, and achieve results with 14x greater accuracy.

Proven Results, 

Trusted by the Industry

Proven Results, 

Trusted by the Industry

Our platform was validated across multiple viral and cancer targets, and beat all of the state of the art models & solutions when solving real-world R&D challenges.

12x

12x

Higher Precision-Recall AUC in T-cell response prediction than the golden standard models.

3x

3x

Higher precision demonstrated in a prospective, head to head, in vivo cancer vaccine study.

100%

100%

Confirmed expression rate, as validated by prospective in vitro study on difficult viral target.

Try it now in our interactive demo

Try it now

Experience it: Go from target protein to de novo antigen design in seconds

Try it now in our interactive demo

Try it now

Experience it: Go from target protein to de novo antigen design in seconds

Try it now in our interactive demo

Try it now

Experience it: Go from target protein to de novo antigen design in seconds

Design next-generation antigen candidates.

Design next-generation antigen candidates.

Design, iterate, apply custom feedback and receive superior candidate within 24h.

Apply different criteria such as: increase or decrease immunogenicity, increase solubility, preserve or modify different regions.

Seamless Computational Workflow

Deepflare's platform integrates the most powerful tools in computational biology from open source (such as RFdiffusion) together with Deepflare's propietary in-house models, into a single, seamless workflow.

Our Approach

Predict and mitigate the
immunogenicity risk

Predict and mitigate the
immunogenicity risk

The Validation Crisis

The majority of antigen design models, such as netMHCpan 4.2, are benchmarked on biased data, creating a cycle of inflated metrics that seem to work well in silico, but fail miserably when tested in vitro & in vivo.

01
The Wrong Target
The Usability Barrier
Business model
The Validation Crisis

The majority of antigen design models, such as netMHCpan 4.2, are benchmarked on biased data, creating a cycle of inflated metrics that seem to work well in silico, but fail miserably when tested in vitro & in vivo.

01
The Wrong Target
The Usability Barrier
Business model
The Validation Crisis

The majority of antigen design models, such as netMHCpan 4.2, are benchmarked on biased data, creating a cycle of inflated metrics that seem to work well in silico, but fail miserably when tested in vitro & in vivo.

The Wrong Target
The Usability Barrier
Business model
The Validation Crisis

The majority of antigen design models, such as netMHCpan 4.2, are benchmarked on biased data, creating a cycle of inflated metrics that seem to work well in silico, but fail miserably when tested in vitro & in vivo.

The Wrong Target
The Usability Barrier
Business model

Get started for
free today

Gain 12x higher accuracy, intuitive bench-ready tools, and technology validated in prospective in-vivo studies.

Get started for
free today

Gain 12x higher accuracy, intuitive bench-ready tools, and technology validated in prospective in-vivo studies.

Get started for
free today

Gain 12x higher accuracy, intuitive bench-ready tools, and technology validated in prospective in-vivo studies.

Copyright Deepflare® 2025. All rights reserved.

Copyright Deepflare® 2025. All rights reserved.

Copyright Deepflare® 2025. All rights reserved.